FFS. Yes AMRN could still go lower. I’m layering in . Will add more probably if it hits $2.50 I’m not trying to hit the absolute bottom
Mkt cap is now $1.1B … over $400m of that is cash on hand Even if U value this on the EU market only …you have an enterprise cost of $700m for a company launching an approved drug with 10 yr exclusivity . A launch that’s been delayed due to Omicron …. But CAD patients will resume MD chk ups when this Covid surge pass’s …. and Vazkepa is likely to be prescribed for many secondary prevention patients